Adoptive T Cell treatment market Analysis (2023 - 2030)
The global Adoptive T Cell treatment market was worth $5.52 billion in 2021, and it is estimated to increase at a CAGR of 20.2 percent from 2022 to 2027.
In terms of growth, the pandemic has had a huge impact on Adoptive T Cell Therapy. The COVID-19 disease began to spread globally in early 2020, infecting millions of individuals worldwide. Major countries around the world redirected their priority to halting the disease's spread, delaying the prevention, identification, and treatment of other chronic conditions such as cancer. The government-imposed blockade of various countries has an impact on life science and biopharmaceutical production. The lockdown resulted in a shortage of raw materials, supply chain interruptions, and contract terminations to save costs, all of which hampered the market's growth. However, due to the easing of restrictions and the resuming of R&D activities and clinical trials, the market is likely to bounce back and gain speed in the future years. The industry is progressing because to increased public knowledge of medical services, as well as favorable government laws and regulations. The US Food and Drug Administration (USFDA) recently approved T-cell therapies to treat children with acute lymphoblastic leukemia (ALL) and adults with advanced lymphomas. As a result, it is estimated that producers would benefit from favorable prospects, and the market will grow.
An increased use of T-cell therapeutic immunity systems is a major factor affecting the sector. Furthermore, an increase in the number of cancer patients worldwide is estimated to propel the industry forward during the forecast period. Variation in illness patterns and an increase in public awareness efforts are estimated to help the sector gain traction in the coming years.
In an effort to increase the global footprints and product ranges, prominent market players are pursuing strategies such as product launches, clinical trials, new research, and seeking regulatory approvals. These techniques assist them in meeting rising consumer demand. Major corporations are forming alliances for research and development in order to create novel cures and to reach a larger worldwide client base.
Key Market Insights:
- Based on type, CAR T Cell Therapy has dominated the market in 2021 and is projected to maintain its dominance during the forecast period. CAR T-cell therapy is a sort of adoptive cell immunotherapy that uses genetically modified CAR T-cells to kill cancer cells. To battle cancers and malignant cells, T-cells are extracted and augmented with specific chimeric antigen receptor components before being re-infused into the body. CAR T-cells have proven to be particularly efficient in treating blood cancers. CAR T-cell treatment is estimated to grow at a CAGR of 15.7 percent over the forecast period.
- Based on indications, The Adoptive T Cell Therapy Market can be divided into Hematologic Malignancies and Solid Tumors. Hematologic Malignancies holds the majority percentage of total revenue. CAR-T cell treatments have made significant progress in the treatment of hematological malignancies, resulting in a saturation of leading market competitors in this field. As a result, companies have shifted their focus to the development of solid tumor therapy in order to grab the less-explored market.
- Based on end user, hospitals hold the majority of the adoptive T cell therapy market. Hospitals and cancer research centers place a high priority on providing quick therapeutic care and releasing patients as soon as feasible after treatment. Hospitals provide a more convenient outpatient method than inpatient hospital systems while still providing high-quality care. During the projected period, clinics and ambulatory facilities with all of the necessary and current t-cell treatment methods and oncologists are poised to grow at rate of 13.2 percent.
- Based on region, North America dominated the Adoptive T-cell therapy market in 2021, accounting for 40 percent of total revenue. Due to the presence of good research, a commercial base, and a high number of clinical trials for T-cell therapy being conducted in the United States, the market in the region has dominated. Furthermore, the increasing number of regulatory approvals in the United States and Canada, as well as the shifting reimbursement landscape in the region, has accelerated the adoption of these medicines, resulting in significant market growth. In addition, the presence of a significant number of medical institutes that offer CAR-T cell therapies contributes to the growth of the regional market.
- TCR2 Therapeutics Inc, Pfizer, Amgen, Novartis AG, Fate Therapeutics, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, Bluebird bio, Inc., Arcellx, Biodesix, Inc., and Laurus Labs are among the major players in the global adoptive cell therapy market. The Adoptive T Cell Therapy market is estimated to become more competitive as new players enter the industry. Due to their innovation and new product development in the Adoptive T-Cell therapy market, Kite Pharma and Novartis AG currently dominate the market.
MARKET SEGMENTATION:
By Type:
- CAR-T cell Therapy
- T Cell Receptor
- Tumor Infiltrating Lymphocytes (TIL)
- Others
By Indication:
- Lymphoma
- Leukemia
- Myeloma
- Melanoma
- Brain & Central Nervous System
- Liver Cancer
By End User:
- Hospitals
- Cancer Research Centers
- Others
By Region
- North America
- Europe
- Asia Pacific
- Rest of the World
For More Info, Request Sample Copy Of This Report @
